Part D results
CMS's year-end Part D reconciliation, 2022–2024. When a plan's actual drug costs land well above its bid, CMS shares the loss through risk sharing (the "risk corridors"); when they land well below, the plan pays CMS back. A large positive amount means the plan's drug bid was badly underpriced. 2024 is the latest year CMS has published.
How to read this
Risk sharing: positive = CMS paid the plan (costs ran over the bid by more than the corridor); negative = the plan paid CMS. These are CMS's settled figures. Plans also report risk sharing in their MLR filings, sometimes as an estimate made before CMS settled, so a filing can differ.
Per member per year: risk sharing ÷ Part D member-months × 12. Part D member-months include stand-alone drug plan (PDP) members.
CMS's reconciliation also settles reinsurance (catastrophic drug costs) and low-income cost sharing; those are pass-through subsidies, not a sign of profit or loss, so they're shown on contract pages only.
| 2024 | 2023 | 2022 | 3-year total | Per member per year2024 | Part D members2024 avg | |
|---|---|---|---|---|---|---|
| H3954 Geisinger Gold | $5.3M | −$437K | −$265K | $4.6M | $103 | 51,350 |
| H3924 Geisinger Gold | $1.1M | $230K | $778K | $2.2M | $25 | 46,451 |
| H2624 HealthTeam Advantage | $58.7K | $20.3K | $46.8K | $126K | $21 | 2,842 |
| H9808 HealthTeam Advantage | $310K | −$620K | $33.7K | −$277K | $22 | 14,198 |
| H2064 LIFE Geisinger | −$1.1M | −$170K | −$614K | −$1.9M | −$2,768 | 390 |
Red = CMS paid the plan. Sorted by the 3-year total. Parent totals add up each contract under its current parent; CMS also publishes its own parent rollup, which can differ where contracts changed hands.